Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691–2700

Article  PubMed  Google Scholar 

Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19:638–651

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(1999–2014):e1991

Google Scholar 

Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864–873

Article  PubMed  Google Scholar 

Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251–260

Article  CAS  PubMed  Google Scholar 

Eslam M, Ahmed A, Després J-P, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743–753

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023;2023:101133

Google Scholar 

Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int. 2024;18:964–972

Article  PubMed  Google Scholar 

Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann Hepatol. 2024;29:101512

Article  PubMed  Google Scholar 

Pan Z, Eslam M, panel of c. The MASLD criteria overlook a number of adolescent patients with severe steatosis. J Hepatol 2024;81(2):e80–e81

Pan Z, Shiha G, Esmat G, Mendez-Sanchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44:1567–1574

Article  CAS  PubMed  Google Scholar 

Ramirez-Mejia MM, Jimenez-Gutierrez C, Eslam M, George J, Mendez-Sanchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18:168–178

Article  PubMed  Google Scholar 

Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH, Group WMCRW. Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD, MAFLD, or Both. J Hepatol 2024.

De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol. 2024;80:e61–e62

Article  CAS  PubMed  Google Scholar 

Staufer K, Stauber RE. Steatotic liver disease: Metabolic dysfunction, alcohol, or both? Biomedicines. 2023;11:2108

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fouad Y, Elwakil R, Elsahhar M, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int. 2021;41:255–260

Article  PubMed  Google Scholar 

Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int 2024;44(7):1567–1574

Pan Z, Eslam M. The MASLD criteria overlook a number of adolescent patients with severe steatosis. J Hepatol 2024;81(2): e80–e81

Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH. Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD, MAFLD, or Both. J Hepatol 2024.

Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int 2024.

Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol. 2020;26(16):1861–1878

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eslam M, Fan J-G, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol. 2020;5:713–715

Article  PubMed  Google Scholar 

Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;2022:1–11

Google Scholar 

Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013;11:1–9

Article  Google Scholar 

Semmler G, Balcar L, Wernly S, et al. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Front Endocrinol (Lausanne). 2023;14:1244405

Article  PubMed  Google Scholar 

Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2012;5:199–207

Article  Google Scholar 

Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64:34–46

Article  CAS  PubMed  Google Scholar 

Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40–52

Article  PubMed  Google Scholar 

Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506–514

Article  CAS  PubMed  Google Scholar